GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of ...

GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...